SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals™ Solutions | COVID-19 Vaccine Research

EXPEDITE COVID-19 VACCINE STUDIES WITHOUT COMPROMISING DATA QUALITY

COVID-19 vaccine research requires condensed timelines, flexible modes of conduct to meet participants where they are, and the highest quality data possible. Signant Health is prepared to meet these challenges with the experience and resources necessary to support studies of this magnitude, complexity, and urgency.

FASTER TRIALS, UNCOMPROMISED DATA ACCURACY

Take advantage of our decades of experience implementing eCOA in vaccine studies, which includes Signant's standard reactogenicity diary. With support from our science, medicine, and global clinical trial operations expertise, accelerate your COVID-19 vaccine studies without compromising endpoint data quality.

MANAGE LARGE-SCALE STUDIES WITH EASE

COVID-19 vaccine studies require substantial participant populations and sites to support them. Our RTSM, eConsent, and eCOA solutions will help you efficiently enroll and randomize participants, manage study supplies, and collect accurate data for studies involving tens of thousands of participants.

ADAPTIVE TRIAL DATA MANAGEMENT

When you partner with Signant, we ensure accuracy and precision of endpoint data. Our team completes data cleaning activities in time for interim analyses and design adaptations, allowing your team to derive insights, make quick decisions, and move rapidly between phases.

PARTICIPANT SAFETY IS PARAMOUNT

We share your primary goal of keeping participants safe during COVID-19 studies. Our safety-focused solutions minimize site visits, ensure consistent ratings, support BYOD data collection, and adapt study supply management techniques to ensure seamless transition between study phases and maintain trial data integrity.

SIMPLIFIED PHASE IV SAFETY AND EFFICACY DATA COLLECTION

Signant's eCOA, Telemedicine, and Patient Concierge solutions help researchers collect long term safety PRO data, minimize in-person site visit requirements, and improve participant retention in long-term COVID-19 vaccine follow up studies.

COMMON LIBRARY MEASURES USED IN CORONAVIRUS

- Signant's standard reactogenicity diary
- EQ-5D
- COVID-19 illness diary

ASK US FOR A COMPLETE LIST.

Signant recently helped a leading sponsor commence a complex 45,000-patient phase II/III COVID-19 vaccine study in one third of the usual time, helping the sponsor achieve emergency use authorization by enabling reliable and accurate evidence generation.

SIGNANT'S VACCINE RESEARCH EXPERIENCE IN THE PAST 5 YEARS

Modality

20+ BYOD

70+ Provisioned

Phases

II III IV

3,500+ Sites

30+ Countries

40+ Languages

140,000+ Patients

95+ Trials

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

RTSM

Rater Training & Qualification

eConsent



DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics

MEET THE EXPERTS